X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6822) 6822
Publication (577) 577
Book Review (80) 80
Newsletter (35) 35
Newspaper Article (11) 11
Magazine Article (7) 7
Book Chapter (4) 4
Conference Proceeding (2) 2
Dissertation (2) 2
Transcript (2) 2
Paper (1) 1
Trade Publication Article (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
docetaxel (6155) 6155
humans (5425) 5425
oncology (4598) 4598
index medicus (4050) 4050
female (3572) 3572
chemotherapy (3548) 3548
middle aged (3491) 3491
aged (3288) 3288
male (3168) 3168
cancer (2493) 2493
adult (2439) 2439
antineoplastic combined chemotherapy protocols - therapeutic use (2259) 2259
treatment outcome (1938) 1938
taxoids - administration & dosage (1717) 1717
antineoplastic combined chemotherapy protocols - adverse effects (1678) 1678
paclitaxel (1420) 1420
care and treatment (1362) 1362
breast neoplasms - drug therapy (1281) 1281
cisplatin (1163) 1163
taxoids - adverse effects (1146) 1146
lung neoplasms - drug therapy (1133) 1133
breast cancer (1114) 1114
aged, 80 and over (1108) 1108
trial (1087) 1087
pharmacology & pharmacy (1070) 1070
therapy (1056) 1056
metastasis (1033) 1033
carcinoma, non-small-cell lung - drug therapy (1015) 1015
antineoplastic agents - therapeutic use (987) 987
medicine & public health (961) 961
prostate cancer (951) 951
disease-free survival (938) 938
research (926) 926
survival (904) 904
neoplasm staging (877) 877
drug administration schedule (864) 864
clinical trials (827) 827
antineoplastic agents - adverse effects (802) 802
drug therapy (789) 789
taxoids - therapeutic use (773) 773
paclitaxel - administration & dosage (712) 712
survival analysis (694) 694
antineoplastic agents (682) 682
analysis (677) 677
breast neoplasms - pathology (675) 675
combination (656) 656
cancer therapies (648) 648
survival rate (634) 634
hematology, oncology and palliative medicine (630) 630
neoplasm metastasis (629) 629
antimitotic agents (627) 627
antineoplastic combined chemotherapy protocols - administration & dosage (627) 627
cisplatin - administration & dosage (617) 617
gemcitabine (615) 615
lung cancer, non-small cell (613) 613
carcinoma (601) 601
lung cancer (601) 601
paclitaxel - adverse effects (599) 599
deoxycytidine - analogs & derivatives (579) 579
lung neoplasms - pathology (574) 574
phase-ii trial (572) 572
retrospective studies (569) 569
prostatic neoplasms - drug therapy (557) 557
patients (554) 554
antineoplastic agents - administration & dosage (550) 550
prognosis (550) 550
doxorubicin (545) 545
toxicity (541) 541
carboplatin (532) 532
carcinoma, non-small-cell lung - pathology (509) 509
health aspects (508) 508
dose-response relationship, drug (503) 503
fluorouracil (486) 486
taxoids (485) 485
deoxycytidine - administration & dosage (484) 484
disease progression (480) 480
fluorouracil - administration & dosage (472) 472
radiotherapy (461) 461
non-small cell lung cancer (460) 460
tumors (460) 460
cancer research (459) 459
phase-iii trial (459) 459
oncology, experimental (443) 443
paclitaxel - analogs & derivatives (440) 440
multicenter (439) 439
open-label (432) 432
phase-ii (428) 428
cell lung-cancer (426) 426
dosage and administration (424) 424
respiratory system (419) 419
animals (418) 418
pharmacology/toxicology (418) 418
randomized-trial (418) 418
kaplan-meier estimate (415) 415
nivolumab (413) 413
urology & nephrology (413) 413
mitoxantrone (405) 405
adenocarcinoma - drug therapy (400) 400
capecitabine (393) 393
immunotherapy (393) 393
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6808) 6808
Japanese (46) 46
French (23) 23
German (18) 18
Chinese (13) 13
Spanish (9) 9
Korean (6) 6
Italian (3) 3
Polish (3) 3
Portuguese (2) 2
Arabic (1) 1
Lithuanian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Supportive Care in Cancer, ISSN 0941-4355, 7/2015, Volume 23, Issue 7, pp. 1969 - 1977
Weekly or tri-weekly docetaxel treatment mandates the use of dexamethasone to prevent toxicity. However, the adverse effects of prophylactic steroid use are... 
Infection | Pain Medicine | Hyperglycemia | Nursing | Rehabilitation Medicine | Corticosteroids | Medicine & Public Health | Docetaxel | Oncology | Nursing Management/Nursing Research | GLUCOCORTICOID-INDUCED HYPERGLYCEMIA | DEXAMETHASONE | TAXANE TOXICITIES | ACUTE LYMPHOCYTIC-LEUKEMIA | PHASE-II | BREAST-CANCER | DIABETES-MELLITUS | WEEKLY PACLITAXEL | INDUCTION THERAPY | ONCOLOGY | HEALTH CARE SCIENCES & SERVICES | REHABILITATION | STEROID USE | Lung Neoplasms - drug therapy | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Dexamethasone - administration & dosage | Drug Administration Schedule | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Middle Aged | Risk Factors | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Dexamethasone - adverse effects | Male | Breast Neoplasms - drug therapy | Infection - chemically induced | Young Adult | Antineoplastic Agents, Hormonal - adverse effects | Taxoids - administration & dosage | Hyperglycemia - chemically induced | Adult | Female | Aged | Retrospective Studies | Taxoids - adverse effects | Cohort Studies | Antimitotic agents | Complications and side effects | Usage | Chemotherapy | Dexamethasone | Antibiotics | Blood sugar | Antineoplastic agents | Risk factors | Cancer | Side effects | Infections | Steroids | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
Journal of Functional Foods, ISSN 1756-4646, 12/2015, Volume 19, pp. 451 - 463
Docetaxel is widely used in the treatment of non-small cell lung cancer. Fungal immunomodulatory proteins of (FIP- ) and (FIP- ) possess immunomodulatory and... 
Myelotoxicity | Fungal immunomodulatory proteins (FIPs) | G-CSF | Bone microarchitecture | Docetaxel | Metastases | COLONY-STIMULATING FACTOR | CELLULAR-IMMUNITY | FOOD SCIENCE & TECHNOLOGY | BONE-MARROW | LUNG-CANCER CELLS | GANODERMA-LUCIDUM | EDIBLE-MUSHROOM | INTERFERON-GAMMA | FIP-FVE | PROSTATE-CANCER | FLAMMULINA-VELUTIPES
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2013, Volume 368, Issue 25, pp. 2385 - 2394
In a prospective, randomized, phase 3 trial of crizotinib as second-line therapy in patients who had disease progression while receiving a platinum-based... 
REARRANGEMENT | MEDICINE, GENERAL & INTERNAL | GEFITINIB | ONCOLOGY | EML4-ALK FUSION GENE | CLINICAL-TRIALS | PHASE-III | LYMPHOMA | OPEN-LABEL | DOCETAXEL | EGFR | Glutamates - therapeutic use | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Glutamates - adverse effects | Guanine - analogs & derivatives | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Young Adult | Taxoids - therapeutic use | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Guanine - adverse effects | Guanine - therapeutic use | Taxoids - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Pemetrexed | Disease-Free Survival | Protein Kinase Inhibitors - therapeutic use | Quality of Life | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Tyrosine | Intravenous administration | Biomedical research | Lung cancer | Liver | Fatigue | Chromosome rearrangements | Cancer therapies | Patients | Lymphoma | Metastases | Ovarian cancer | Quality of life | Confidence intervals | Chemotherapy | Dyspnea | Alopecia | Platinum | Lymphomas | Respiration | Pharmaceutical industry | Protein-tyrosine kinase
Journal Article
by Zhang, JT and Fu, FM and Lin, YX and Chen, YZ and Lu, MJ and Chen, MY and Yang, PD and Huang, M and Wang, C
ONCOTARGET, ISSN 1949-2553, 10/2017, Volume 8, Issue 46, pp. 81636 - 81648
Capecitabine in addition to anthracycline-taxane based regimens for patients with early breast cancer (EBC) has been reported in previous clinical trials, but... 
early breast cancer | side-effects | SURGICAL ADJUVANT BREAST | DOXORUBICIN PLUS CYCLOPHOSPHAMIDE | BEVACIZUMAB | COMBINATION THERAPY | PHASE-III | DOCETAXEL | PACLITAXEL | CELL BIOLOGY | capecitabine | EPIRUBICIN | disease-free survival | NEOADJUVANT CHEMOTHERAPY | overall survival | THYMIDINE PHOSPHORYLASE
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10024, pp. 1163 - 1177
Journal Article
Clinical Breast Cancer, ISSN 1526-8209, 2011, Volume 11, Issue 6, pp. 349 - 356
Journal Article
Journal of Chinese Pharmaceutical Sciences, ISSN 1003-1057, 12/2017, Volume 26, Issue 12, pp. 895 - 899
Journal Article
JAMA, ISSN 0098-7484, 01/2017, Volume 317, Issue 1, pp. 37 - 47
Journal Article
Journal of Urology, The, ISSN 0022-5347, 2015, Volume 194, Issue 6, pp. 1537 - 1547
Journal Article